Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial.
about
Mu-opioid antagonists for opioid-induced bowel dysfunctionConsensus statement AIGO/SICCR diagnosis and treatment of chronic constipation and obstructed defecation (part II: treatment)The effects of herkinorin, the first mu-selective ligand from a salvinorin A-derived scaffold, in a neuroendocrine biomarker assay in nonhuman primatesOpioid-induced constipation: advances and clinical guidanceClinical review: Thinking outside the box--an iconoclastic view of current practiceTreatment of opioid-induced gut dysfunctionVgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain.Electro-acupuncture to prevent prolonged postoperative ileus: a randomized clinical trial.Methylnaltrexone antagonizes opioid-mediated enhancement of HIV infection of human blood mononuclear phagocytesManaging opioid-induced constipation in advanced illness: focus on methylnaltrexone bromide.Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation.Methylnaltrexone: its pharmacological effects alone and effects on morphine in healthy volunteersMethylnaltrexone in the treatment of opioid-induced constipationMethylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects.A review of methylnaltrexone, a peripheral opioid receptor antagonist, and its role in opioid-induced constipation.Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus.Randomized placebo-controlled study of intravenous methylnaltrexone in postoperative ileusNew treatments for irritable bowel syndrome in womenEmerging drugs for chronic constipation.Methylnaltrexone: treatment for opioid-induced constipation.Management of opioid-induced constipation in cancer patients: focus on methylnaltrexone.Methylnaltrexone for the treatment of opioid-induced constipation.Treatment with Methylnaltrexone and IVIG for Paraneoplastic Gastrointestinal Dysmotility.Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits.The effect of methylnaltrexone on the side effects of intrathecal morphine after orthopedic surgery under spinal anesthesia.Meta-analysis of oro-cecal transit time in fasting subjects.Methylnaltrexone for opioid-induced constipation in patients at the end of life.Methylnaltrexone for opioid-induced constipation in patients with advanced illness: a 3-month open-label treatment extension study.Effects of remifentanil on the esophagogastric junction and swallowing.Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans.Subjective, psychomotor, and physiological effects of oxycodone alone and in combination with ethanol in healthy volunteers.Analgesics and AntipyreticsOral methylnaltrexone is efficacious and well tolerated for the treatment of opioid-induced constipation in patients with chronic noncancer pain receiving concomitant methadone
P2860
Q24243268-701CD5E7-8DDB-4607-B26B-484EED5EBABAQ24633140-15F83212-8607-4ACD-AF2D-C8DA7DADB3A2Q24652924-9983345C-3974-49D9-A35B-D38A24604C16Q26765571-9FC20E66-16F5-4DDB-81B5-C8BBCCBCEED3Q26865095-8D889225-5ABD-4F97-BAA0-76E3827170A1Q28284578-3CA37EF9-E4D5-4F7E-9C4F-7EC930338847Q33296232-7E32B491-D215-4544-A846-5004066FA4B9Q33520508-5BB2D57D-0108-457F-AEF7-595997B4773FQ33564922-40B41C6B-CF18-4A6A-90EF-E90232B1C9D8Q33593875-D3E66102-9C59-4167-9710-047056BBCA3BQ33715430-F8E380FC-CC75-4BBA-856A-7C4E5C07E8A7Q33973870-CBC917A5-AC1B-46FC-9963-422658A351E5Q34966995-281D9F60-8EAE-4785-A347-A35E4536BC8AQ35026245-78C73406-1F10-4E31-9728-2965BE4BA91DQ36458384-EF6EA386-4F9F-409D-8FB0-3614A498011BQ36852958-BCB95F21-D3D7-4EF9-82E8-B20D752B4558Q36936210-EAE4DB16-5AC6-4D6C-A3E8-84ED98992E3CQ37077184-068FF695-9E1C-403D-A387-C3355D8052B4Q37120300-E3EBB2CC-1116-47CC-907F-FA31C5B2A1A2Q37570550-EA39B35B-9ABC-4345-B5A7-C33BD6FE99FBQ37783847-0869D742-0B15-4F12-98E5-D5DCE1DB3CB4Q37993108-263A9263-9FCC-40BE-8FC6-254FC656937CQ38069607-2107662E-9C1D-4469-913F-C2544D48D5A0Q38202638-269B64DB-3768-4D97-952E-6C492E265173Q38772298-011476EE-9925-4FF5-8E48-B6D972BE9879Q39211193-4AAF4FA7-135B-41BB-B30E-B39587E1A7ECQ43474298-CC407822-6935-446A-831E-C6AA33225794Q44350880-AF8EA26F-5F75-459E-8048-708D13039DDEQ44351073-43094989-031D-483E-94B6-B621FE96DC23Q45770192-61774B17-4D7B-4CE8-B4A4-4582759F51B5Q46438870-66F38BBD-2701-4ED7-B411-D9A633000BF9Q48261582-2CEA226A-7014-4BA3-BC8B-C648DDF95BA2Q56113559-3B701B49-D39B-459C-A9B2-B0EC7C1D5073Q58694488-E232643F-96BE-4828-8BE6-AAB48E919EFA
P2860
Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Effects of subcutaneous methyl ...... ized placebo-controlled trial.
@en
Effects of subcutaneous methyl ...... ized placebo-controlled trial.
@nl
type
label
Effects of subcutaneous methyl ...... ized placebo-controlled trial.
@en
Effects of subcutaneous methyl ...... ized placebo-controlled trial.
@nl
prefLabel
Effects of subcutaneous methyl ...... ized placebo-controlled trial.
@en
Effects of subcutaneous methyl ...... ized placebo-controlled trial.
@nl
P2093
P356
P1476
Effects of subcutaneous methyl ...... ized placebo-controlled trial.
@en
P2093
Chun-Su Yuan
Joachim Osinski
Joseph F Foss
Michael O'Connor
Theodore Karrison
P304
P356
10.1124/JPET.300.1.118
P407
P577
2002-01-01T00:00:00Z